Advertise on podcast: GvHD Hub

The GvHD Hub spoke with Robert Zeiser, University of Freiburg, Freiburg, DE. We asked, How can ECP be positioned in the current GvHD treatment landscape as a steroid-free intervention?​​ During this interview, Zeiser discusses the potential positioning of extracorporeal photopheresis (ECP) in the treatment landscape for acute graft-versus-host disease (GvHD) and chronic GvHD, noting that corticosteroids remain the standard first-line treatment in both settings. He highlights the steroid-sparing potential of ECP and considers its role as a second- or later-line treatment option, either alone or in combination with other agents, including ruxolitinib. He also emphasizes the need for further prospective studies to clarify the optimal sequencing of ECP and its use in combination with other therapies. Intended for healthcare professionals. This educational resource is independently supported by Therakos. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

The GvHD Hub spoke with Daniel Wolff, University Hospital Regensburg, Regensburg, DE. We asked, What are the key clinical considerations for the use of ECP in SR-GvHD?​​ In this interview, Wolff discusses factors guiding the use of extracorporeal photopheresis in steroid-refractory graft-versus-host disease. Treatment decisions should account for patient- and disease-related factors, including cytopenias, risk of infection or malignant relapse, and organ involvement, alongside practical considerations, such as venous access, treatment frequency, and the commitment required for long-term therapy. Intended for healthcare professionals. This educational resource is independently supported by Therakos. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

The GvHD Hub spoke with Andrew Harris, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the challenges involved in enrolling pediatric patients in cGvHD clinical trials? During this interview, Harris discusses key barriers to enrolling pediatric patients with chronic graft-versus-host disease (cGvHD) in clinical trials, including the limited number of specialist centers with expertise in managing pediatric cGvHD and the resulting need for some children and their families to travel considerable distances to participating sites. He also highlights how the rarity of cGvHD in children may make it difficult to identify eligible patients for clinical trials. Intended for healthcare professionals. This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

The GvHD Hub spoke with Steven Pavletic, Bethesda, US. We asked, What are the key barriers to patient participation in cGvHD clinical trials? During this interview, Pavletic discusses key factors that may impact patient participation in chronic graft-versus-host disease (cGvHD) clinical trials, including the practical and emotional demands associated with trial involvement, as well as concerns regarding treatment-emergent adverse events and potential long-term effects of investigational therapies. He highlights the importance of empowering patients and involving them in decisions about their care, with clear communication helping to ensure that patients are well informed and have realistic expectations about trial participation. Intended for healthcare professionals. This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

The GvHD Hub spoke with Corey Cutler, Dana-Farber Cancer Institute, Boston, US. We asked, What approaches could improve recruitment and retention in cGvHD clinical trials? During this interview, Cutler discusses strategies to promote recruitment and retention of patients in chronic graft-versus-host disease (cGvHD) clinical trials. He highlights the importance of broad eligibility criteria, as well as opportunities for patients to participate in both therapeutic and non-therapeutic cGvHD research. He also emphasizes the need to consider the patient perspective when designing trials, including the time, travel, and assessment burden associated with participation. Intended for healthcare professionals. This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

During the GvHD Hub Steering Committee Meeting in July 2026, key opinion leaders met to discuss how extracorporeal photophoresis (ECP) is used in clinical practice for the treatment of pediatric graft-versus-host disease (GvHD), including benefits and challenges associated with its use. The meeting opened with a presentation from Andrew Harris, and featured a panel discussion with Mohamad Mohty, Corey Cutler, Hildegard Greinix, and Daniel Wolff.    During his presentation, Harris explained that, beyond first-line steroid therapy, the management of GvHD relies on a range of second-line treatment options, noting there are limited data and guidance specific to pediatric patients. Among these, ECP – an immunomodulatory leukapheresis-based therapy – is increasingly being incorporated into clinical practice as a second-line or later treatment. However, its use in pediatric patients remains variable, with no standardized approach. Harris presented a case from his practice involving a 3-year-old patient who developed acute GvHD following transplantation and was treated with ECP. He also discussed the practical and logistical considerations associated with ECP and explored how micro-ECP may overcome some of the challenges limiting ECP use in pediatric patients.    This educational activity is independently supported by Therakos. All content is developed by the steering committee in collaboration with SES. Funders are allowed no influence   Hosted on Acast. See acast.com/privacy for more information.

During the 8th International Chronic Graft-versus-Host Disease Symposium, the GvHD Hub held a symposium on May 22, 2026, titled Evolving treatment strategies in SR‑cGvHD: Optimizing patient selection across current and emerging therapies. Here, we share a presentation by Corey Cutler, Dana-Farber Cancer Institute, Boston, US, describing the impact of clinical manifestations on treatment selection in steroid-refractory chronic graft-versus-host disease (SR-cGvHD).  Cutler provides an overview of the inflammatory and fibrotic mechanisms underlying cGvHD, including the roles of the JAK1/2, ROCK2, and CSF-1R signaling pathways. He outlines the heterogeneous, organ-specific responses observed with targeted therapies and highlights that treatment selection may be informed by consideration of expected organ-specific responses and disease phenotype, with growing efforts to target the underlying biological mechanisms of cGvHD.    This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence Hosted on Acast. See acast.com/privacy for more information.

During the 8th International Chronic Graft-versus-Host Disease Symposium, the GvHD Hub held a symposium on May 22, 2026, titled Evolving treatment strategies in SR‑cGvHD: Optimizing patient selection across current and emerging therapies. Here, we share a presentation by Zinaida Perić, Rijeka, HR, outlining emerging treatment strategies for SR-cGvHD. Perić highlights the growing shift toward targeted approaches that directly address the inflammation and fibrosis associated with cGvHD. She reviews the latest clinical data for several novel agents and combination approaches under evaluation for the treatment of SR-cGvHD, while emphasizing the need for larger-scale studies to confirm clinical benefit. This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

During the 8th International Chronic Graft-versus-Host Disease Symposium, the GvHD Hub held a symposium on May 22, 2026, titled Evolving treatment strategies in SR‑cGvHD: Optimizing patient selection across current and emerging therapies. The symposium closed with a panel discussion that included questions from the audience. The panelists, Zinaida Perić, Daniel Wolff, and Corey Cutler, shared their perspectives on several key topics, including applying learnings from the treatment of other diseases, and the role of combination therapy in cGvHD. This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

During the 8th International Chronic Graft-versus-Host Disease Symposium, the GvHD Hub held a symposium on May 22, 2026, titled “Evolving treatment strategies in SR‑cGvHD: Optimizing patient selection across current and emerging therapies”. Here, we share a presentation by Daniel Wolff, Regensburg, DE, outlining current treatment options for SR-cGvHD.   Wolff reviews available therapeutic options for SR-cGvHD, including key data from pivotal trials of approved and widely adopted therapies. He discusses indications for transitioning to second- and third-line treatments, outlines his approach to managing SR-cGvHD, and highlights remaining unmet treatment needs.   This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

The GvHD Hub spoke with Corey Cutler, Dana-Farber Cancer Institute, Boston, US. We asked, How do you approach later-line sequencing in cGvHD in your clinical practice?  Cutler discusses his approach to selecting second-line and subsequent therapies for patients with cGvHD. He explains that, in his practice, treatment selection is guided primarily by FDA approval status and toxicity profiles, while organ involvement plays a more limited, context-dependent role. He highlights patient comorbidities and practical considerations, such as route of administration and dosing frequency, as additional factors that may influence therapy selection. This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

The GvHD Hub spoke with Robert Zeiser, University of Freiburg, Freiburg, DE. We asked, How might emerging therapies and combination approaches reshape sequencing strategies in cGvHD? During this interview, Zeiser discusses emerging treatment strategies under evaluation in cGvHD, including the latest clinical data for several combination approaches and novel agents. Whilst encouraging results have been observed to date, further research is needed to define their optimal placement within treatment sequencing pathways. This educational resource is independently supported by  Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

The GvHD Hub spoke with Daniel Wolff, University Hospital Regensburg, Regensburg, DE. We asked, What factors drive your decision to switch from first- to second-line therapy for cGvHD? During this interview, Wolff discusses factors that guide his decision to escalate from first-line corticosteroids to second-line therapy in cGvHD. When considering a treatment switch, both efficacy and tolerability of steroid therapy should be evaluated, alongside consideration of other patient-related factors such as age, organ involvement, and infectious complications. This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

During the 52nd Annual Meeting of the EBMT, the GvHD Hub held a symposium on March 24, 2026, titled “Focusing GvHD care through the eyes of providers and patients: Practical insights on ECP”. Here, we share a presentation by Matea Meden, describing her experience with GvHD. Matea describes her journey with GvHD, focusing on its profound impact on her physical health, emotional wellbeing, and overall quality of life. She outlines her treatment pathway, which included steroids, ruxolitinib, and extracorporeal photopheresis (ECP). She highlights both the practical and physical challenges of ECP alongside the gradual clinical improvements she experienced. Matea also shares advice for patients with GvHD, encouraging them to trust the ECP treatment process, communicate openly with their healthcare team, and draw strength from their family, peers, and support networks. This educational resource is independently supported by Therakos. All content was developed by the faculty in collaboration with SES. Funders were allowed no influence. Hosted on Acast. See acast.com/privacy for more information.

During the 52nd Annual Meeting of the EBMT, the GvHD Hub held a symposium on March 24, 2026, titled “Focusing GvHD care through the eyes of providers and patients: Practical insights on ECP”. Here, we share a presentation by Hildegard Greinix, Vienna, AT, describing her approach to treating GvHD with ECP. Greinix presents two patient case studies illustrating the use of ECP for the management of both acute and chronic GvHD. In both cases, she notes that ECP could be considered a second‑line or later treatment option, either as monotherapy or in combination with other agents, due to its immunomodulatory mechanism of action and favorable safety profile. She also explores key considerations and patient factors that inform treatment selection and initiation. This educational resource is independently supported by Therakos. All content was developed by the faculty in collaboration with SES. Funders were allowed no influence. Hosted on Acast. See acast.com/privacy for more information.